Glycomine
Investment area
Venture Investments
Region
North America
Date of investment
July 2019
Glycomine focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. There are 100 known glycosylation disorders. Glycomine’s lead drug, GLM101, is designed to address the largest congenital disorder of glycosylation, PMM2-CDG, through mannose-1-phophate replacement therapy.